Global Viral and Non-Viral Vector Manufacturing Market – Analysis and Forecast (2023-2030)

Industry Insight by Vector Type (Viral Vector (Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, and Other Viral Vector) and Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, and Other Non-Viral Vector)), by Disease (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, and Other Diseases), by Application (Gene Therapy, Vaccinology, Cell Therapy, and Others), and Geography (U.S., Canada, Germany, U.K., France, China, Japan, India, and Rest of the World)

Industry Overview

The global viral and non-viral vector manufacturing market is anticipated to grow from USD 1.6 billion in 2022 to USD 24.3 billion by 2030, registering a CAGR of 18.45% during the forecast period 2023-2030. Innovative therapies that involve vectors, such as gene therapy and cell therapy, have had a tremendous impact on medicine in the last few decades. Therapies that require genetic modification, such as the introduction of therapeutic deoxyribonucleic acid (DNA)/gene into a patient's body or cell, have shown significant impact in the treatment of a variety of fatal diseases, including cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, etc.  The creation and standardization of numerous viral and non-viral vectors to meet unmet medical needs have been emphasized in light of the promising outcomes shown by these vector-based therapeutics in several preclinical and clinical investigations.

The viral vector and non-viral manufacturing industries are projected to benefit from the COVID-19 epidemic. there are many COVID-19 vaccine candidates which have entered into clinical trials and including viral vector vaccines. These vaccines are very likely to be among the COVID-19 vaccines that have been approved for use worldwide.

Market Segmentation

Insight by Vector Type

Based on vector type, the global viral and non-viral vector manufacturing market is segmented into viral vector and non-viral vectors. The viral vector is further divided into Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, and Other Viral Vectors. The non-viral vector is further divided into Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, and Other Non-Viral Vectors. Because of the ease of application in major target diseases such as cancer and genetic disorders, the retroviral vectors segment dominated the market.

Insight by Disease

Based on disease, the global viral and non-viral vector manufacturing market is classified into cancer, genetic disease, infectious disease, cardiovascular disease, and other diseases. The cancer segment is anticipated to contribute to the largest share during the forecast period owing to the rising number of clinical trials and availability of approved viral vector-based cancer drugs. Furthermore, the rising number of patients suffering from cancer and modern healthcare facilities will propel the growth of the market. 

The genetic disorders segment is anticipated to grow at a faster pace during the forecast period owing to the rising number of research activities like hemophilla A & B, Huntington’s disease, sickle cell anemia, etc. and a robust genetic therapy pipeline will accelerate the growth of the market.

Insight by Application

Based on application, the global viral and non-viral vector manufacturing market is divided into gene therapy, vaccinology, cell therapy, and others. Gene therapy is anticipated to witness the largest share in the market owing to the rising number of gene therapy clinical trials for chronic and infectious diseases like cancer, cardiovascular diseases, and neurodegenerative diseases globally.

Viral and Non-Viral Vector Manufacturing Market Report Coverage

Industry Dynamics

Growth Drivers

Viral vectors and non-viral vectors have attracted substantial global attention as a potential therapeutic method to treat a wide variety of severe diseases, resulting in increased investments in drug research and commercialization. The global viral and non-viral vector manufacturing market is growing due to the increasing popularity of gene and cell therapy products (which use vectors), increased adoption of nucleic acid therapeutics in non-viral vectors, mounting synergistic activities, and increased funding activities supporting vector-based therapeutic research will bolster the growth of the market. Furthermore, rising rates of genetic abnormalities, cancer, and deadly diseases, as well as an expanding number of clinical trials and a solid pipeline of gene and cell therapy products along with vector-based vaccines, are all driving factors for market expansion.

Challenges

The challenges faced by the viral and non-viral vector manufacturing market include massive cost involved in gene therapy, surging manufacturing cost of viral vectors, complications involved in large scale production of viral vectors along with low transfection efficiency for non-viral vectors might impede the growth of the market.

Opportunities

The rapid rise in genetically modified therapies, increased demand for synthetic genes along the advent of next-generation vectors has resulted in a significant increase in demand for various vectors for basic and pharmacological research, creating opportunities for companies with expertise in targeted gene delivery.

Geographic Overview

North America contributes the largest share in the viral and non-viral vector manufacturing market owing to the increased implementation of viral vector-based gene therapies to treat chronic and rare diseases, rising number of regenerative medicine companies, availability of funds along with the availability of FDA approved gene therapies, thereby bolstering the growth in the region.

Competitive Insight

The global viral and non-viral vector manufacturing market is made up of both established and new companies. Several companies are attempting to enter the market and maintain competition by attempting to launch new manufacturing capacities, expanding their businesses, collaborating with viral and non-viral vector manufacturing companies to innovate new cell therapies, and vaccines for several diseases, or developing proprietary viral and non-viral vector platforms.

Catalent Cell & Gene Therapy is a technology, development, and manufacturing partner for breakthrough therapies that leads the industry. Its extensive cell therapy portfolio includes expertise in a wide range of cell types, which include CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, oncolytic viruses, and live virus vaccines, with strong knowledge in viral vector discovery, scale-up, and production for gene treatments.

GenScript creates a GMP platform for vector production, including viral and non-viral vectors. Gene and cell therapy (GCT) has the potential to revolutionize medicine by offering long-term and perhaps curative treatment options for a variety of disorders. Plasmids and viruses in various quality levels are offered as part of the new medication development process to meet requirements at various stages with a quick turnaround time.

In October 2021, Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium, and Oxford Biomedica (OXB) stated that Boehringer Ingelheim has exercised its options on intellectual property and know-how from the partners in order to advance and accelerate the development of a potential new treatment option for CF patients. In the partnership, IP Group grants exclusive global rights to develop, manufacture, register, and commercialize this lentiviral vector-based gene therapy for the treatment of cystic fibrosis on behalf of the three GTC host universities. The GTC also contributes expertise in pre-clinical research and clinical gene therapy development. OXB is complementing Boehringer Ingelheim's expertise in the development of novel breakthrough therapies for respiratory diseases with its leading expertise in manufacturing lentiviral vector-based therapies.

In October 2021, Catalent, one of the prominent leaders in facilitating biopharma, cell, gene, and consumer health partners to significantly improve the development, launch, and supply of better patient treatments across multiple modalities, has announced a $230 million expansion project at its gene therapy campus in Harmans, Maryland, resulting in adding three more commercial-scale viral vector manufacturing suites, as well as associated support facilities and services, to meet growing customer demand.

Some of the industry players in the global viral and non-viral vector manufacturing market include Boehringer Ingelheim International GmbH, Catalent, Inc, GenScript ProBio, Lonza, Merck KGaA, Oxford Biomedica, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., and Evonik Industries AG.

The Viral and Non-Viral Vector Manufacturing Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2021–2027.

Segments Covered in the Report

• By Vector Type
  • Viral Vector
    • Adenoviral Vector
    • Retroviral Vector
    • Adeno-Associated Viral Vector
    • Lentiviral Vector
    • Vaccinia Viral Vector
    • Other Viral Vector
  • Non-Viral Vector
    • Plasmid DNA
    • Lipid-Based Non-Viral Vector
    • Polymer-Based Non-Viral Vector
    • Other Non-Viral Vector
• By Disease
  • Cancer
  • Genetic Disease
  • Infectious Disease
  • Cardiovascular Disease
  • Other Diseases
• By Application
  • Gene Therapy
  • Vaccinology
  • Cell Therapy
  • Others

Region Covered in the Report

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • South Korea
  • Rest of Asia-Pacific
• Rest of the World (RoW)
  • Brazil
  • Saudi Arabia
  • South Africa
  • U.A.E.
  • Other Countries

To explore more about this report - Request a free sample copy

The Viral and Non-Viral Vector Manufacturing Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2023–2030.

Segments Covered in the Report

•    By Vector Type

- Viral Vector

> Adenoviral Vector
> Retroviral Vector
> Adeno-Associated Viral Vector
> Lentiviral Vector
> Vaccinia Viral Vector
> Other Viral Vector

- Non-Viral Vector

> Plasmid DNA
> Lipid-Based Non-Viral Vector
> Polymer-Based Non-Viral Vector
> Other Non-Viral Vector

•    By Disease

- Cancer
- Genetic Disease
- Infectious Disease
- Cardiovascular Disease
- Other Diseases

•    By Application

- Gene Therapy
- Vaccinology
- Cell Therapy
- Others

Region Covered in the Report

•    North America

- U.S.
- Canada
- Mexico

•    Europe

- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe

•    Asia-Pacific (APAC)

- China
- Japan
- India
- South Korea
- Rest of Asia-Pacific

•    Rest of the World (RoW)

- Brazil
- Saudi Arabia
- South Africa
- U.A.E.
- Other Countries

1.    Research Overview

        1.1.    The Report Offers
        1.2.    Market Coverage
                1.2.1.    By Vector Type
                1.2.2.    By Disease
                1.2.3.    By Application
                1.2.4.    By Region
        1.3.    Research Phases
        1.4.    Limitations
        1.5.    Market Methodology
                1.5.1.    Data Sources
                        1.5.1.1. Primary Research
                        1.5.1.2. Secondary Research
                1.5.2.    Methodology
                        1.5.2.1. Data Exploration
                        1.5.2.2. Forecast Parameters
                        1.5.2.3. Data Validation
                        1.5.2.4. Assumptions
                1.5.3.    Study Period & Data Reporting Unit

2.    Executive Summary

3.    Industry Overview

        3.1.    Industry Dynamics
                3.1.1.    Market Growth Drivers
                3.1.2.    Market Restraints
                3.1.3.    Key Market Trends
                3.1.4.    Major Opportunities
        3.2.    Industry Ecosystem
                3.2.1.    Porter’s Five Forces Analysis
                3.2.2.    Recent Development Analysis
                3.2.3.    Value Chain Analysis
        3.3.    Competitive Insight
                3.3.1.    Competitive Position of Industry Players
                3.3.2.    Market Attractive Analysis
                3.3.3.    Market Share Analysis

4.    Global Market Estimate and Forecast

        4.1.    Global Market Overview
        4.2.    Global Market Estimate and Forecast to 2030

5.    Market Segmentation Estimate and Forecast

        5.1.    By Vector Type
                5.1.1.    Viral Vector
                        5.1.1.1. Market Definition
                        5.1.1.2. Market Estimation and Forecast to 2030 
                                5.1.1.2.1. Adenoviral Vector
                                5.1.1.2.2. Retroviral Vector
                                5.1.1.2.3. Adeno-Associated Viral Vector
                                5.1.1.2.4. Lentiviral Vector
                                5.1.1.2.5. Vaccinia Viral Vector
                                5.1.1.2.6. Other Viral Vector
                5.1.2.    Non-Viral Vector
                        5.1.2.1. Market Definition
                        5.1.2.2. Market Estimation and Forecast to 2030
                                5.1.2.2.1. Plasmid DNA
                                5.1.2.2.2. Lipid-Based Non-Viral Vector
                                5.1.2.2.3. Polymer-Based Non-Viral Vector
                                5.1.2.2.4. Other Non-Viral Vector
        5.2.    By Disease
                5.2.1.    Cancer
                        5.2.1.1. Market Definition
                        5.2.1.2. Market Estimation and Forecast to 2030
                5.2.2.    Genetic Disease
                        5.2.2.1. Market Definition
                        5.2.2.2. Market Estimation and Forecast to 2030
                5.2.3.    Infectious Disease
                        5.2.3.1. Market Definition
                        5.2.3.2. Market Estimation and Forecast to 2030
                5.2.4.    Cardiovascular Disease
                        5.2.4.1. Market Definition
                        5.2.4.2. Market Estimation and Forecast to 2030
                5.2.5.    Other Diseases
                        5.2.5.1. Market Definition
                        5.2.5.2. Market Estimation and Forecast to 2030
        5.3.    By Application
                5.3.1.    Gene Therapy
                        5.3.1.1. Market Definition
                        5.3.1.2. Market Estimation and Forecast to 2030
                5.3.2.    Vaccinology
                        5.3.2.1. Market Definition
                        5.3.2.2. Market Estimation and Forecast to 2030
                5.3.3.    Cell Therapy
                        5.3.3.1. Market Definition
                        5.3.3.2. Market Estimation and Forecast to 2030
                5.3.4.    Others
                        5.3.4.1. Market Definition
                        5.3.4.2. Market Estimation and Forecast to 2030
                        
6.    North America Market Estimate and Forecast

        6.1.    By Vector Type
        6.2.    By Disease
        6.3.    By Application
        6.4.    By Organization Size
        6.5.    By Vertical
        6.6.    By Country
                6.6.1.    U.S. Market Estimate and Forecast
                6.6.2.    Canada Market Estimate and Forecast
                6.6.3.    Mexico Market Estimate and Forecast

7.    Europe Market Estimate and Forecast

        7.1.    By Vector Type
        7.2.    By Disease
        7.3.    By Application
        7.4.    By Country
                7.4.1.    Germany Market Estimate and Forecast
                7.4.2.    France Market Estimate and Forecast
                7.4.3.    U.K. Market Estimate and Forecast
                7.4.4.    Italy Market Estimate and Forecast
                7.4.5.    Spain Market Estimate and Forecast
                7.4.6.    Rest of Europe Market Estimate and Forecast

8.    Asia-Pacific Market Estimate and Forecast

        8.1.    By Vector Type
        8.2.    By Disease
        8.3.    By Application
        8.4.    By Country
                8.4.1.    China Market Estimate and Forecast
                8.4.2.    Japan Market Estimate and Forecast
                8.4.3.    India Market Estimate and Forecast
                8.4.4.    South Korea Market Estimate and Forecast
                8.4.5.    Singapore Market Estimate and Forecast
                8.4.6.    Rest of Asia-Pacific Market Estimate and Forecast

9.    Rest of the World (RoW) Market Estimate and Forecast

        9.1.    By Vector Type
        9.2.    By Disease
        9.3.    By Application
        9.4.    By Country
                9.4.1.    Brazil Market Estimate and Forecast
                9.4.2.    Saudi Arabia Market Estimate and Forecast
                9.4.3.    South Africa Market Estimate and Forecast
                9.4.4.    Other Countries Market Estimate and Forecast

10.    Company Profiles

        10.1.    Boehringer Ingelheim International GmbH
                10.1.1.    Snapshot
                10.1.2.    Overview
                10.1.3.    Offerings
                10.1.4.    Financial Insight
                10.1.5.    Recent Developments
        10.2.    Catalent, Inc
                10.2.1.    Snapshot
                10.2.2.    Overview
                10.2.3.    Offerings
                10.2.4.    Financial Insight
                10.2.5.    Recent Developments
        10.3.    GenScript ProBio
                10.3.1.    Snapshot
                10.3.2.    Overview
                10.3.3.    Offerings
                10.3.4.    Financial Insight
                10.3.5.    Recent Developments
        10.4.    Lonza
                10.4.1.    Snapshot
                10.4.2.    Overview
                10.4.3.    Offerings
                10.4.4.    Financial Insight
                10.4.5.    Recent Developments
        10.5.    Merck KGaA
                10.5.1.    Snapshot
                10.5.2.    Overview
                10.5.3.    Offerings
                10.5.4.    Financial Insight
                10.5.5.    Recent Developments
        10.6. Oxford Biomedica
                10.6.1.    Snapshot
                10.6.2.    Overview
                10.6.3.    Offerings
                10.6.4.    Financial Insight
                10.6.5.    Recent Developments
        10.7.    Sartorius AG
                10.7.1.    Snapshot
                10.7.2.    Overview
                10.7.3.    Offerings
                10.7.4.    Financial Insight
                10.7.5.    Recent Developments
        10.8.    Takara Bio Inc.
                10.8.1.    Snapshot
                10.8.2.    Overview
                10.8.3.    Offerings
                10.8.4.    Financial Insight
                10.8.5.    Recent Developments
        10.9.    Thermo Fisher Scientific Inc.
                10.9.1.    Snapshot
                10.9.2.    Overview
                10.9.3.    Offerings
                10.9.4.    Financial Insight
                10.9.5.    Recent Developments
        10.10. Evonik Industries AG
                10.10.1. Snapshot
                10.10.2. Overview
                10.10.3. Offerings
                10.10.4. Financial Insight
                10.10.5. Recent Developments

11.    Appendix

        11.1.    Exchange Rates
        11.2.    Abbreviations

Note: Financial insight and recent developments of different companies are subject to the availability of information in the secondary domain.

List of Tables

Table 1 Sources
Table 2 Study Periods
Table 3 Data Reporting Unit
Table 4 Global Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2018-2022 (USD Billion)
Table 5 Global Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2023–2030  (USD Billion)
Table 6 Global Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2022 (USD Billion)
Table 7 Global Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2023–2030  (USD Billion)
Table 8 Global Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2022 (USD Billion)
Table 9 Global Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2023–2030  (USD Billion)
Table 10 Global Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2022 (USD Billion)
Table 11 Global Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2023–2030  (USD Billion)
Table 12 North America Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2018-2022 (USD Billion)
Table 13 North America Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2023–2030  (USD Billion)
Table 14 North America Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2022 (USD Billion)
Table 15 North America Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2023–2030  (USD Billion)
Table 16 North America Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2022 (USD Billion)
Table 17 North America Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2023–2030  (USD Billion)
Table 18 North America Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2022 (USD Billion)
Table 19 North America Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2023–2030  (USD Billion)
Table 20 Europe Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2018-2022 (USD Billion)
Table 21 Europe Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2023–2030  (USD Billion)
Table 22 Europe Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2022 (USD Billion)
Table 23 Europe Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2023–2030  (USD Billion)
Table 24 Europe Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2022 (USD Billion)
Table 25 Europe Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2023–2030  (USD Billion)
Table 26 Europe Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2022 (USD Billion)
Table 27 Europe Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2023–2030  (USD Billion)
Table 28 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2018-2022 (USD Billion)
Table 29 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2023–2030  (USD Billion)
Table 30 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2022 (USD Billion)
Table 31 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2023–2030  (USD Billion)
Table 32 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2022 (USD Billion)
Table 33 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2023–2030  (USD Billion)
Table 34 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2022 (USD Billion)
Table 35 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2023–2030  (USD Billion)
Table 36 RoW Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2018-2022 (USD Billion)
Table 37 RoW Viral and Non-Viral Vector Manufacturing Market Size, By Vector Type, 2023–2030  (USD Billion)
Table 38 RoW Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2022 (USD Billion)
Table 39 RoW Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2023–2030  (USD Billion)
Table 40 RoW Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2022 (USD Billion)
Table 41 RoW Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2023–2030  (USD Billion)
Table 42 RoW Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2022 (USD Billion)
Table 43 RoW Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2023–2030  (USD Billion)
Table 44 Snapshot – Boehringer Ingelheim International GmbH
Table 45 Snapshot – Catalent, Inc
Table 46 Snapshot – GenScript ProBio
Table 47 Snapshot – Lonza
Table 48 Snapshot – Merck KGaA
Table 49 Snapshot – Oxford Biomedica
Table 50 Snapshot – Sartorius AG
Table 51 Snapshot – Takara Bio Inc.
Table 52 Snapshot – Thermo Fisher Scientific Inc.
Table 53 Snapshot – Evonik Industries AG

List of Figures

Figure 1 Market Coverage
Figure 2 Research Phases
Figure 3 Secondary Sources for Different Parameters
Figure 4 Methodology
Figure 5 Data Mining & Exploration
Figure 6 Data Triangulation
Figure 7 Assumptions for Market Estimation and Forecast
Figure 8 Market Synopsis
Figure 9 Global Viral and Non-Viral Vector Manufacturing Market - Growth Drivers and Restraints
Figure 10 Competitive Benchmark
Figure 11 Global Viral and Non-Viral Vector Manufacturing Market Highlight
Figure 12 Global Viral and Non-Viral Vector Manufacturing Market Size, By Service, 2018-2030 (USD Billion)
Figure 13 Global Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2030 (USD Billion)
Figure 14 Global Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2030 (USD Billion)
Figure 15 Global Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2030 (USD Billion)
Figure 16 North America Viral and Non-Viral Vector Manufacturing Market Highlight
Figure 17 North America Viral and Non-Viral Vector Manufacturing Market Size, By Service, 2018-2030 (USD Billion)
Figure 18 North America Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2030 (USD Billion)
Figure 19 North America Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2030 (USD Billion)
Figure 20 North America Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2030 (USD Billion)
Figure 21 Europe Viral and Non-Viral Vector Manufacturing Market Highlight
Figure 22 Europe Viral and Non-Viral Vector Manufacturing Market Size, By Service, 2018-2030 (USD Billion)
Figure 23 Europe Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2030 (USD Billion)
Figure 24 Europe Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2030 (USD Billion)
Figure 25 Europe Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2030 (USD Billion)
Figure 26 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Highlight
Figure 27 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, By Service, 2018-2030 (USD Billion)
Figure 28 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2030 (USD Billion)
Figure 29 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2030 (USD Billion)
Figure 30 Asia-Pacific Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2030 (USD Billion)
Figure 31 RoW Viral and Non-Viral Vector Manufacturing Market Highlight
Figure 32 RoW Viral and Non-Viral Vector Manufacturing Market Size, By Service, 2018-2030 (USD Billion)
Figure 33 RoW Viral and Non-Viral Vector Manufacturing Market Size, By Disease, 2018-2030 (USD Billion)
Figure 34 RoW Viral and Non-Viral Vector Manufacturing Market Size, By Application, 2018-2030 (USD Billion)
Figure 35 RoW Viral and Non-Viral Vector Manufacturing Market Size, by Region, 2018-2030 (USD Billion)